The Neuroimaging Core will continue to provide support for all neuroimaging studies performed on AD and related dementias by ADRC and ADRC-associated investigators. The Core builds on its successes with the development and distribution of methodologies for acquisition and interpretation of a comprehensive functional magnetic resonance imaging (MRI) protocol at 3.0 Tesla and to extend services to encompass positron emission tomography (PET). Procedures for acquiring, archiving and managing all the clinical MR imaging examinations performed on patients referred for ADRC evaluation are in place. Ready access to fMRI technology for paradigm design and image analysis continues to encourage new investigators and novel approaches into AD research. Based on current results from the Core, such fMRI studies offer new insight into innate brain responses to disease and subsequent dysfunction. Such functional parameters may prove useful clinically. As PET remains a focus of activity within the ADRC and uses MRI resources, support for this modality has also been encompassed into the Core. This expanded role should serve to foster efficient use of combined imaging modalities and facilitate communication between investigators using these resources. Through interactions with other research grants, the expanded Core faculty enable greater access to a broader scope of support and expertise without substantial increase in cost.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Besser, Lilah M; Kukull, Walter A; Teylan, Merilee A et al. (2018) The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses. J Neuropathol Exp Neurol 77:717-726
Lingler, Jennifer H; Roberts, J Scott; Kim, Hyejin et al. (2018) Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimers Dement (Amst) 10:413-420
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Lancour, Daniel; Naj, Adam; Mayeux, Richard et al. (2018) One for all and all for One: Improving replication of genetic studies through network diffusion. PLoS Genet 14:e1007306
Tudorascu, Dana L; Minhas, Davneet S; Lao, Patrick J et al. (2018) The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimers Dement (Amst) 10:332-339
DeKosky, Steven T; Jaffee, Michael; Bauer, Russell (2018) Long-term Mortality in NFL Professional Football Players: No Significant Increase, but Questions Remain. JAMA 319:773-775
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Snitz, Beth E; Wang, Tianxiu; Cloonan, Yona Keich et al. (2018) Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimers Dement 14:734-742

Showing the most recent 10 out of 667 publications